Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Operating Expenses (2016 - 2025)

BioCorRx's Operating Expenses history spans 16 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 55.5% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $6.4 million, up 31.43%, while the annual FY2024 figure was $5.1 million, 32.32% up from the prior year.
  • Operating Expenses for Q3 2025 was $2.6 million at BioCorRx, up from $1.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $2.6 million in Q3 2025 and bottomed at $841650.0 in Q4 2023.
  • The 5-year median for Operating Expenses is $1.1 million (2022), against an average of $1.3 million.
  • The largest annual shift saw Operating Expenses plummeted 55.25% in 2021 before it soared 70.75% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $1.3 million in 2021, then dropped by 5.77% to $1.3 million in 2022, then plummeted by 33.66% to $841650.0 in 2023, then surged by 33.64% to $1.1 million in 2024, then surged by 129.46% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Operating Expenses are $2.6 million (Q3 2025), $1.6 million (Q2 2025), and $1.1 million (Q1 2025).